Eckert & Ziegler SE
ISIN: DE0005659700
WKN: 565970
05 December 2024 09:30AM

EQS-News: Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments

Eckert & Ziegler SE · ISIN: DE0005659700 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 2044547

EQS-News: Eckert & Ziegler SE / Key word(s): Incoming Orders/Alliance
Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments

05.12.2024 / 09:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


Berlin, 5 December 2024. Eckert & Ziegler, one of the world’s largest providers of isotopes for medical, scientific and industrial use, and Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced the signing of a global supply agreement for the medical radionuclides Actinium-225 (Ac-225) and Lutetium-177 (Lu-177).

Following limited global availability, alongside increasing demand for Ac-225, which comes with intricate manufacturing complexities, this collaboration is a significant step forward in accelerating Ariceum’s novel targeted radiopharmaceutical pipeline programs.

Under the terms of the agreement, Eckert & Ziegler will supply Ariceum with the required quantities of non-carrier-added (n.c.a.) Ac-225 and Lu-177. Both radionuclides will be used to radiolabel Ariceum’s proprietary lead radiopharmaceutical drug (SS0110) satoreotide targeting hard-to-treat cancers in clinical studies and subsequent commercial phases. The agreement also includes options for expansion to other drugs as well as the use of additional radionuclides in preparation for future commercialization activities.

Dr. Harald Hasselmann, Chief Executive Officer of Eckert & Ziegler, commented: “In collaborating with Ariceum, we support their mission to develop innovative radiopharmaceuticals for the benefit of patients. Both the production start for Ac-225, announced earlier this week, and the successful European approval of Theralugand®, show that our goal is to sustainably reduce the shortage of high-quality radioisotopes. We aim to foster the progress of novel treatments in clinical trials and beyond, and thus contribute to saving lives.”

Manfred Rüdiger, Chief Executive Officer of Ariceum Therapeutics, said: “This important global supply agreement with Eckert & Ziegler for n.c.a. Ac-225 and Lu-177 will ensure an adequate supply of radionuclide isotopes to conduct our clinical trials. We are looking forward to working with the Eckert & Ziegler team to build a robust supply chain and to reliably deliver targeted theranostic treatments for patients with hard-to-treat cancers. Our lead radiopharmaceutical drug, satoreotide is a first-in-class, antagonist of the somatostatin receptor 2 (SSTR2) labelled with Ac-225 to enter clinical development in small cell lung cancer and in Merkel Cell Carcinoma very soon.”

About Eckert & Ziegler SE
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler SE shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

About Ariceum Therapeutics, GmbH

Ariceum Therapeutics (Ariceum) is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of ‘Marie Curie’ whose discovery of radium and polonium have been huge contributions to finding treatments for cancer.
Ariceum’s lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan (“satoreotide”), is an antagonist of the somatostatin type 2 (SSTR2) receptor which is overexpressed in neuroendocrine tumours (NETs) and some aggressive cancers such as small cell lung cancer (SCLC), or Merkel Cell Carcinoma (MCC), all of which have few treatment options and poor prognosis. Satoreotide is being developed as a ‘theranostic pair’ for the combined diagnosis and targeted radionuclide treatment of these tumours. Ariceum is also developing a radiolabelled PARP-inhibitor (ATT001), currently in Phase 1 clinical development under the trial name CITADEL-123. ATT001 was part of the acquisition of Theragnostics Ltd which was closed in June 2023.
Ariceum Therapeutics, launched in 2021, acquired all rights to Satoreotide from Ipsen. Ipsen remains a shareholder in the Company. Ariceum is headquartered in Berlin, with operations in Germany, Switzerland, Australia, United Kingdom and United States of America and with activities currently across the globe.
Ariceum is led by a highly experienced management team and supported by specialist investors including EQT Life Sciences (formerly LSP), HealthCap, Pureos Bioventures, Andera Partners and Earlybird Venture Capital. For further information, please visit  www.ariceum-therapeutics.com.

Contact
Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
jan.schoepflin@ezag.de/ karolin.riehle@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com

Ariceum Therapeutics
Manfred Rüdiger, CEO
info@ariceum-therapeutics.com

Optimum Strategic Communications
Zoe Bolt Charlotte Hepburne-Scott, Elena Bates
Tel: +44 (0) 20 3882 9621
ariceum@optimumcomms.com



05.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Eckert & Ziegler SE
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-0
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX, TecDax,
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2044547

 
End of News EQS News Service

2044547  05.12.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2044547&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2018 2019 2020 2021 2022 2023 2024e
Sales1 168,71 178,49 176,14 180,44 222,26 246,09 290,00
EBITDA1,2 32,14 43,13 44,64 57,04 55,52 58,83 0,00
EBITDA-Margin3 19,05 24,16 25,34 31,61 24,98 23,91 0,00
EBIT1,4 23,39 32,06 33,69 47,45 44,54 45,45 60,00
EBIT-Margin5 13,86 17,96 19,13 26,30 20,04 18,47 20,69
Net Profit (Loss)1 16,89 22,48 23,11 34,66 29,75 26,77 0,00
Net-Margin6 10,01 12,60 13,12 19,21 13,39 10,88 0,00
Cashflow1,7 21,21 40,43 36,79 33,86 34,30 47,40 0,00
Earnings per share8 0,78 1,07 1,11 1,66 1,41 1,26 1,54
Dividend per share8 0,30 0,42 0,45 0,50 0,50 0,05 0,50
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: Forvis Mazars

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Eckert & Ziegler
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
565970 DE0005659700 SE 943,84 Mio € 25.05.1999 Halten 9F4MJGG3+WR
* * *
PE 2025e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
27,52 26,29 1,05 49,04 4,27 19,91 3,84
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
0,50 0,05 0,50 1,12%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
18.06.2025 13.05.2025 08.08.2025 14.11.2024 27.03.2025
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
+0,41%
44,58 €
ATH 141,40 €
+5,41% +14,32% +21,44% +24,09% +675,30%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2024          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 by Gereon Kruse #BGFL